ClinicalTrials.gg
CompletedNCT01571453Updated Oct 13, 2014Results posted

Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries

A Phase 3 interventional study of Vortioxetine (Lu AA21004) and Venlafaxine extended release in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-10-13.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
437
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
26th of 54
437 · median 413
Started
2012
with 2 others
Phase 3
31 of 54
1 open now
Registered
24th of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 26th largest by enrollment, is one of 3 that started in 2012, is one of 31 in phase 3, and was the 24th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

This study will be conducted with the aim of investigating the efficacy, safety and tolerability of 10 mg/day Vortioxetine in Asian patients compared to an approved active comparator (venlafaxine extended release 150 mg/day).

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • MDD
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient suffers from recurrent MDD as the primary diagnosis according to DSM-IVTR™ criteria. The current Major Depressive Episode (MDE) should be confirmed using the Mini International Neuropsychiatric Interview (MINI)
  • The patient has a MADRS total score ≥26
  • The patient has a CGI-S score ≥4
  • The reported duration of the current MDE is ≥3 months.

Other inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • The patient meets any of the exclusion criteria listed in the protocol or, in the investigator's opinion, is unlikely to comply with the protocol or is unsuitable for any reason.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
437 participants (actual)

Study arms

  • Experimental
    Vortioxetine (Lu AA21004)

    Drug: Vortioxetine (Lu AA21004)

  • Active comparator
    Venlafaxine extended release

    Drug: Venlafaxine extended release

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in MADRS Total Score at Week 8

    Montgomery and Asberg Depression Rating Scale (MADRS) is a ten-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). Definitions of severity are provided at two-point intervals. The total score of the ten items ranges from 0 to 60. The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change in CGI-S Score From Baseline to Week 8

    Clinical Global Impression Scale - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients). Higher score indicates that the subject is more ill, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

    Time frame: Baseline and Week 8

  2. CGI-I Score at Week 8

    The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not. Higher score = more affected.

    Time frame: Week 8

  3. Change in HAM-A Total Score From Baseline to Week 8

    Hamilton Anxiety Rating Scale (HAM-A) is a 14-item rating scale designed to assess the global anxiety. Each symptom is rated from 0 (absent) to 4 (maximum severity). The total score of the 14 items ranges from 0 to 56. Higher score indicates greater anxiety, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

    Time frame: Baseline and Week 8

  4. MADRS Response at Week 8 (Response Defined as a ≥50% Decrease in the MADRS Total Score From Baseline)

    Time frame: Week 8

  5. Remission at Week 8 (Remission Defined as a MADRS Total Score ≤10)

    Time frame: Week 8

  6. Number of Adverse Events

    Time frame: Baseline to Week 12

07

Results

Posted Oct 13, 2014

Participant flow

In- or outpatients with a primary diagnosis of recurrent of Major Depressive Disorder (MDD) were recruited for this study from China, South Korea, Taiwan, and Thailand.

Participant flow — Overall Study
MilestoneVortioxetineVenlafaxine
Started211226
Completed173164
Not completed3862
Withdrew: Adverse event1432
Withdrew: Lack of efficacy83
Withdrew: Non-compliance24
Withdrew: Protocol violation15
Withdrew: Withdrawal of consent513
Withdrew: Lost to follow-up42
Withdrew: Administrative or other reason(s)43

Outcome measures

PrimaryChange From Baseline in MADRS Total Score at Week 8

Montgomery and Asberg Depression Rating Scale (MADRS) is a ten-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). Definitions of severity are provided at two-point intervals. The total score of the ten items ranges from 0 to 60. The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline in MADRS Total Score at Week 8
units on a scaleVortioxetineVenlafaxine
Change From Baseline in MADRS Total Score at Week 8-19.36 ± 0.70-18.16 ± 0.68
Statistical analysis
  • Vortioxetine vs Venlafaxine · ANCOVA · p = 0.199 (No adjustments for multiple comparisons were made.) · Mean difference (final values): -1.20 · 95% CI -3.03 to 0.63LOCF was used.
SecondaryChange in CGI-S Score From Baseline to Week 8

Clinical Global Impression Scale - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients). Higher score indicates that the subject is more ill, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change in CGI-S Score From Baseline to Week 8
units on a scaleVortioxetineVenlafaxine
Change in CGI-S Score From Baseline to Week 8-2.26 ± 0.09-2.12 ± 0.09
Statistical analysis
  • Vortioxetine vs Venlafaxine · ANCOVA · p = 0.228 (No adjustments for multiple comparisons were made.) · Mean difference (final values): -0.15 · 95% CI -0.39 to 0.09LOCF was used.
SecondaryCGI-I Score at Week 8

The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not. Higher score = more affected.

Time frame:
Week 8
Reported as:
Mean · units on a scale
CGI-I Score at Week 8
units on a scaleVortioxetineVenlafaxine
CGI-I Score at Week 81.99 ± 0.082.14 ± 0.08
Statistical analysis
  • Vortioxetine vs Venlafaxine · ANCOVA · p = 0.174 (No adjustments for multiple comparisons were made.) · Mean difference (final values): -0.14 · 95% CI -0.35 to 0.06LOCF was used.
SecondaryChange in HAM-A Total Score From Baseline to Week 8

Hamilton Anxiety Rating Scale (HAM-A) is a 14-item rating scale designed to assess the global anxiety. Each symptom is rated from 0 (absent) to 4 (maximum severity). The total score of the 14 items ranges from 0 to 56. Higher score indicates greater anxiety, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change in HAM-A Total Score From Baseline to Week 8
units on a scaleVortioxetineVenlafaxine
Change in HAM-A Total Score From Baseline to Week 8-11.38 ± 0.48-10.56 ± 0.47
Statistical analysis
  • Vortioxetine vs Venlafaxine · ANCOVA · p = 0.207 (No adjustments for multiple comparisons were made.) · Mean difference (final values): -0.82 · 95% CI -2.09 to 0.45LOCF was used.
SecondaryMADRS Response at Week 8 (Response Defined as a ≥50% Decrease in the MADRS Total Score From Baseline)
Time frame:
Week 8
Reported as:
Number · percentage of patients
MADRS Response at Week 8 (Response Defined as a ≥50% Decrease in the MADRS Total Score From Baseline)
percentage of patientsVortioxetineVenlafaxine
MADRS Response at Week 8 (Response Defined as a ≥50% Decrease in the MADRS Total Score From Baseline)66.561.4
Statistical analysis
  • Vortioxetine vs Venlafaxine · Regression, Logistic · p = 0.272 (Wald's Test. No adjustments for multiple comparisons were made.) · Odds ratio (or): 1.25 · 95% CI 0.84 to 1.86
SecondaryRemission at Week 8 (Remission Defined as a MADRS Total Score ≤10)
Time frame:
Week 8
Reported as:
Number · percentage of patients
Remission at Week 8 (Remission Defined as a MADRS Total Score ≤10)
percentage of patientsVortioxetineVenlafaxine
Remission at Week 8 (Remission Defined as a MADRS Total Score ≤10)43.141.4
Statistical analysis
  • Vortioxetine vs Venlafaxine · Regression, Logistic · p = 0.731 (Wald's Test. No adjustments for multiple comparisons were made.) · Odds ratio (or): 1.07 · 95% CI 0.73 to 1.58
SecondaryNumber of Adverse Events
Time frame:
Baseline to Week 12

No measurements were reported for this outcome.

Adverse events

Collected over Baseline to 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vortioxetine—2/211 (0.9%)90/211 (42.7%)
Venlafaxine—8/226 (3.5%)124/226 (54.9%)
Most frequent serious events
Most frequent serious events
EventVortioxetineVenlafaxine
Suicide attemptPsychiatric disorders1/2112/226
DepressionPsychiatric disorders1/2110/226
Vertigo positionalEar and labyrinth disorders0/2111/226
AstheniaGeneral disorders0/2111/226
Intentional overdoseInjury, poisoning and procedural complications0/2111/226
Ligament sprainInjury, poisoning and procedural complications0/2111/226
AnxietyPsychiatric disorders0/2111/226
Major depressionPsychiatric disorders0/2111/226
VaricoceleReproductive system and breast disorders0/2111/226
Most frequent other events
Most frequent other events
EventVortioxetineVenlafaxine
NauseaGastrointestinal disorders51/21153/226
DizzinessNervous system disorders18/21132/226
Dry mouthGastrointestinal disorders12/21124/226
Decreased appetiteMetabolism and nutrition disorders10/21123/226
HeadacheNervous system disorders17/21116/226
ConstipationGastrointestinal disorders9/21118/226
InsomniaPsychiatric disorders5/21117/226
Accidental overdoseInjury, poisoning and procedural complications10/21112/226
DyspepsiaGastrointestinal disorders11/2119/226

Baseline characteristics

The all-patients-treated set (APTS) comprises all randomized patients who took at least one dose of IMP. Baseline age and gender is based on the APTS. Baseline efficacy outcome measures is based on the full-analysis set (FAS).

Age, Continuous
Age, Continuous(years)VortioxetineVenlafaxineTotal
Mean39.6 ± 12.440.7 ± 12.340.1 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)VortioxetineVenlafaxineTotal
Female123139262
Male8887175
MADRS total score
MADRS total score(units on a scale)VortioxetineVenlafaxineTotal
Mean32.3 ± 4.632.3 ± 4.532.3 ± 4.6
HAM-A total score
HAM-A total score(units on a scale)VortioxetineVenlafaxineTotal
Mean20.6 ± 7.321.1 ± 7.020.9 ± 7.1
CGI-S score
CGI-S score(units on a scale)VortioxetineVenlafaxineTotal
Mean4.8 ± 0.74.9 ± 0.74.9 ± 0.7
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Wang G, Zhao K, Reynaud-Mougin C, Loft H, Ren H, Eriksen HF, Ettrup A. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder. Curr Med Res Opin. 2020 May;36(5):875-882. doi: 10.1080/03007995.2020.1723072. Epub 2020 Feb 13. PubMed 31990207 ↗
  • Wang G, Gislum M, Filippov G, Montgomery S. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study. Curr Med Res Opin. 2015 Apr;31(4):785-94. doi: 10.1185/03007995.2015.1014028. Epub 2015 Feb 19. PubMed 25650503 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012 and a primary completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2012
First posted
Apr 5, 2012
Start
May 2012
Primary completionActual
Oct 2013
Results first posted
Oct 13, 2014
Last update
Oct 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01571453
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Apr 5, 2012
Start date
May 2012
Primary completion
Oct 2013
Results posted
Oct 13, 2014
Last update
Oct 13, 2014

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion